文献速递肝病

Baveno VII标准灰区患者的肝脏失代偿风险与预测因素:竞争风险分析

Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis.
PubMed 文献 · Aliment Pharmacol Ther · 2023-08-30

研究纳入香港、韩国和法国的前瞻性队列,共2763例代偿性进展期慢性肝病患者,评估Baveno VII灰区患者肝脏失代偿的风险与预测因素。5年累积失代偿发生率在低危组为0.6%、灰区组为4.2%、高危组为11.4%。病因(酒精相关肝病)、白蛋白-胆红素评分和碱性磷酸酶水平与灰区患者失代偿独立相关,联合脾硬度测量可减少灰区分类并维持风险区分度。

要点

  • 灰区患者5年累积失代偿发生率为4.2%(95%CI: 3.1%-5.4%),显著高于低危组0.6%。
  • 酒精相关肝病、白蛋白-胆红素评分和碱性磷酸酶是灰区患者失代偿的独立预测因素。
  • 联合Baveno VII与脾硬度可将灰区患者比例降至12.8%,并保持对低危和高危组的区分度。

核心结论

  • Baveno VII标准灰区患者仍存在较高的肝脏失代偿风险,临床危险因素和脾硬度可进一步进行风险分层。

研究设计与样本

  • 纳入来自香港、韩国和法国的前瞻性队列,共2763例接受瞬时弹性成像检查的代偿性进展期慢性肝病患者。
  • 采用竞争风险回归分析肝脏失代偿风险,以肝细胞癌和非肝相关死亡为竞争事件。

主要发现

  • 2763例代偿性进展期慢性肝病患者中,Baveno VII灰区组1243例(44.9%),高危组536例(19.4%)。
  • 5年累积失代偿发生率:低危组0.6%(95%CI: 0.2%-1.3%),灰区组4.2%(95%CI: 3.1%-5.4%),高危组11.4%(95%CI: 8.7%-14.6%),三组间差异显著。
  • 竞争风险分析显示,在灰区患者中,肝病病因(酒精相关肝病)、白蛋白-胆红素评分和碱性磷酸酶水平与失代偿独立相关。
  • 联合Baveno VII与脾硬度测量使灰区患者比例降至12.8%(在代偿性进展期慢性肝病患者中),同时保持对低危和高危组失代偿的良好区分度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Baveno VII was proposed for non-invasive identification of clinically significant portal hypertension. However, a substantial proportion of patients is classified in the grey zone (i.e., liver stiffness 15-24.9 kPa and/or platelet count <150 × 109 /L). AIMS: To evaluate the risk and predictors of hepatic decompensation in patients in the grey zone, and to determine the prognostic role of spleen stiffness measurement. METHODS: We included prospective cohorts (from Hong Kong, Korea and France) of patients who had undergone transient elastography examination for chronic liver disease. We estimated risk of hepatic decompensation using competing risk regression with hepatocellular carcinoma and non-liver-related death as competing events. RESULTS: We identified 2763 patients with compensated advanced chronic liver disease (cACLD). There were 1243 (44.9%) and 536 (19.4%) patients in the Baveno VII grey zone and high-risk groups, respectively. The cumulative incidence of decompensation at 5 years was significantly different among low-risk (0.6% [95% CI: 0.2%-1.3%]), grey zone 4.2% (95% CI: 3.1%-5.4%) and high-risk groups (11.4% [95% CI: 8.7%-14.6%]). By competing risk analysis, aetiology of liver disease (alcohol-related liver disease), albumin-bilirubin score and alkaline phosphatase level were independently associated with decompensation among patients in the grey zone. The combination of Baveno VII and spleen stiffness significantly reduced patients classified into grey zone (12.8% in cACLD patients), while maintaining high discrimination of decompensation in low- and high-risk groups. CONCLUSIONS: Patients in grey zone of Baveno VII criteria remain at high risk of hepatic decompensation. Clinical risk factors and spleen stiffness can further stratify the risk in such patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lin H, Lai JC, Wong GL, et al. Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis. Aliment Pharmacol Ther. 2023. PMID: 37646318. doi:10.1111/apt.17699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。